한빛사
>
한빛사논문
한빛사논문
- 조회183
Clin. Transl. Med., Mar 2024, 14 (3) e1625 | https://doi.org/10.1002/ctm2.1625
[LETTER TO THE JOURNAL] Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases
Jeong Hyeon Lee1,# Hongchan An2,3,# HyeJi Kwon4,# Su-Jeong Lee3 Young Hye Park3 Ji Sun Hwang3 Min Young Kim3 Hayoung Hwang3 Jeong Yoon Kim4 Seung Jin Lee4 Sung Eun Chang1 Youngsup Song 4
1Department of Dermatology, University of Ulsan College ofMedicine, Asan Medical Center, Seoul, South Korea
2College of Pharmacy and Institute of PharmaceuticalSciences, CHA University, Pocheon, South Korea
3New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation(DGMIF), Daegu, South Korea
4Department of Brain Science, Brain Korea 21 project, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
# These authors contributed equally to this work.
Correspondence : Sung Eun Chang, Youngsup Song
1Department of Dermatology, University of Ulsan College ofMedicine, Asan Medical Center, Seoul, South Korea
2College of Pharmacy and Institute of PharmaceuticalSciences, CHA University, Pocheon, South Korea
3New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation(DGMIF), Daegu, South Korea
4Department of Brain Science, Brain Korea 21 project, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
# These authors contributed equally to this work.
Correspondence : Sung Eun Chang, Youngsup Song
Abstract
No abstract available
논문정보
- LETTER TO THE JOURNAL
- 2024년 03월 (BRIC 등록일 2024-12-04)
- 국내 연구진
- 의약학 > 분자세포의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
